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OBJECTIVE—We tested the hypotheses that in nondiabetic
individuals, partial inhibition of insulin secretion with the ATP-
sensitive K
+ channel agonist (opener) diazoxide, compared with
placebo, results in higher plasma glucose and higher plasma glu-
cagon concentrations after a mixed meal and after administration
of the sulfonylurea glimepiride.
RESEARCH DESIGN AND METHODS—Plasma glucose, in-
sulin, C-peptide, and glucagon concentrations were measured
every 30 min from 260 through 180 min with random-sequence,
double-blind administration of diazoxide (6.0 mg/kg) or placebo
at 230 and 1 min, ingestion of a formula mixed meal (Ensure
Plus) at 0 min after diazoxide and after placebo and, on a separate
occasion, ingestion of glimepiride (4.0 mg) at 0 min (with glucose
infused to prevent hypoglycemia) after diazoxide and after pla-
cebo in 11 healthy young adults.
RESULTS—With diazoxide administration, insulin (P = 0.0016)
and C-peptide (P = 0.0287) concentrations were decreased and
glucose concentrations were increased (e.g., 180-min values of
106 6 4 mg/dL [5.9 6 0.2 mmol/L] compared with 87 6 2 mg/dL
[4.8 6 0.1 mmol/L] with placebo; P , 0.0001), but glucagon con-
centrations were no different after the mixed meal. Similarly, with
diazoxide, C-peptide concentrations were decreased (P = 0.0015)
and glucose concentrations were increased (P , 0.0001), but
glucagon concentrations declined similarly after glimepiride ad-
ministration.
CONCLUSIONS—Partial inhibition of insulin secretion results
in impairment of glucose tolerance after a mixed meal and after
glimepiride administration in the absence of a difference in
glucagon secretion. They underscore the primary glucoregulatory
role of insulin and support the evidence that b-cell secretion is
not the only regulator of a-cell glucagon secretion. Diabetes
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educed pancreatic b-cell insulin secretion causes
hyperglycemia in diabetes. The extent to which
that is the result of reduced b-cell mass, re-
duced function per b-cell, or both, in type 2
diabetes is unknown (1,2), but it has been suggested that
both are required (1). Selective inhibition of b-cell secre-
tion, in the absence of a reduction in b-cell mass, has not
been shown to produce diabetes in humans (1). However,
intravenous and oral administration of diazoxide, an ATP-
sensitive K
+ (KATP) channel agonist (opener), partially
inhibited insulin secretion and raised postabsorptive
plasma glucose concentrations in nondiabetic humans (3).
We therefore tested the hypothesis that partial inhibition of
insulin secretion with diazoxide, compared with placebo,
would result in higher plasma glucose concentrations after
a mixed meal and, on a separate occasion, after adminis-
tration of the sulfonylurea glimepiride (with glucose infused
to prevent hypoglycemia) in nondiabetic individuals.
The regulation of pancreatic a-cell glucagon secretion is
complex and incompletely understood (4–13). It involves
direct signaling of a-cells through an KATP channel-
dependent mechanism (4) and indirect signaling of a-cells
by b-cell (5–9) and d-cell (10) secretory products, the au-
tonomic nervous system (11,12) and gut incretins (13).
Furthermore, the functional relationship between b-cells
and a-cells might be altered by distorted architecture of
the islets in diabetes. Among the array of signals, there is
increasing evidence that b-cell secretory products (5–9),
including insulin (14–16), normally restrain a-cell glucagon
secretion and that 1) a decrease in b-cell secretion, in
concert with a low plasma glucose concentration, stim-
ulates glucagon secretion during hypoglycemia (16–20),
and 2) an increase in b-cell secretion inhibits glucagon
secretion during euglycemia and hyperglycemia (21) in
humans. With respect to the latter, a mixed meal sup-
presses a-cell glucagon secretion when it can stimulate
b-cell insulin secretion (i.e., in nondiabetic individuals) but
stimulates a-cell glucagon secretion when it cannot stim-
ulate b-cell insulin secretion (i.e., in individuals with type
1 diabetes) (21). Similarly, the sulfonylurea glimepiride
suppresses a-cell glucagon secretion when it can stimulate
b-cell insulin secretion but stimulates a-cell glucagon se-
cretion when it cannot stimulate b-cell insulin secretion
(21). Therefore, we also tested the hypothesis that partial
inhibition of insulin secretion with the KATP channel ago-
nist (opener) diazoxide, compared with placebo, would
result in higher plasma glucagon and plasma glucose
concentrations after a mixed meal and, on a separate oc-
casion, after the sulfonylurea glimepiride (with glucose in-
fused to prevent hypoglycemia) in nondiabetic individuals.
RESEARCH DESIGN AND METHODS
Subjects. The study recruited 11 healthy individuals (six women, ﬁve men),
who were a mean 6 SD age 29.8 6 6.2 years and had a BMI of 26.3 6 5.3 kg/m
2.
This study was approved by the Washington University Human Research Pro-
tection Ofﬁce and conducted at the Washington University Clinical Research
Unit (CRU). All participants provided written consent to participate. They were
in good health, as determined by their medical history and a physical exami-
nation, were taking no drugs (aside from an oral contraceptive or a stable dose
of thyroxine), and had fasting plasma glucose and creatinine concentrations,
hematocrits, and electrocardiogram (ECG) results that were within normal
reference ranges.
Experimental design. Subjects reported to the CRU in the morning after an
overnight fast on four occasions. They remained supine throughout each study.
A catheter was inserted into vein in a hand vein, with that hand kept in an
;55°C plexiglas box, for arterialized venous sampling every 30 min from 260
to 180 min. For the glimepiride studies, a catheter was also inserted into an
antecubital vein for glucose infusion. Heart rates and blood pressures were
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ORIGINAL ARTICLEalso monitored (GE Dash 3000, Fairﬁeld, CT) every 30 min, and the ECG was
monitored throughout.
On two occasions, participants received oral 6.0 mg/kg diazoxide (Progly-
cem, Gate Pharmaceuticals, Sellersville, PA) or placebo in random sequence, in
a double-blind fashion at 230 min after a formula mixed meal (Ensure Plus,
350 kcal, 50 g carbohydrate, 13 g protein, and 11 g fat) at 0 min. On two other
occasions, they also received oral diazoxide or placebo at 230 min, followed
by glimepiride (Amaryl, sanoﬁ-aventis, U.S., Bridgewater, NJ), 4.0 mg at 0 min.
Glucose was infused intravenously, determined by bedside plasma glucose
measurements every 5 min, to prevent hypoglycemia after glimepiride in-
gestion.
Analytic methods. Plasma glucose concentrations were measured with a
glucose oxidase method (YSI Glucose Analyzer, Yellow Springs Instruments,
Yellow Springs, OH). Plasma insulin and C-peptide concentrations were
measured with two site chemiluminescent assays (Immulite 1000, Siemens
Corp, Los Angeles, CA). Plasma glucagon concentrations were measured with
the Linco radioimmunoassay (Millipore, Temecula, CA). Plasma epinephrine
and norepinephrine concentrations were measured with a single isotope de-
rivative (radioenzymatic) method (22).
Statistical methods. Except where the SD is speciﬁed, data are reported as
the mean 6 SE. Data related to time and condition (placebo or diazoxide)
were analyzed by repeated-measures mixed-model ANOVA. Modeling was
performed with SAS 9.2 software (SAS Institute, Cary, NC) with the MIXED
procedure. Condition-related P values are reported; values of P , 0.05 were
considered to indicate signiﬁcant differences.
RESULTS
Meal studies. With diazoxide, compared with placebo,
plasma insulin (P = 0.0016) and C-peptide (P = 0.0287)
concentrations were decreased after the mixed meal,
plasma glucose concentrations were increased (P =
0.0001), and plasma glucagon concentrations were no
different (P = 0.6602; Fig. 1, Tables 1 and 2). Plasma epi-
nephrine concentrations were unaltered (P = 0.1392), but
plasma norepinephrine concentrations increased (P ,
0.0001) after diazoxide administration (Table 1). Heart
rates were slightly higher (P , 0.0001) and diastolic blood
pressures were slightly lower (P = 0.0039) after diazoxide
(Table 2).
Glimepiride studies. With diazoxide, compared with
placebo, plasma insulin concentrations after glimepiride
tended to be decreased (P = 0.0649), plasma C-peptide
concentrations were decreased (P = 0.0015), and plasma
glucose concentrations were increased (P , 0.0001; Fig. 2,
Tables 1–3), despite glucose infusion rates that were ;50%
of those after glimepiride with placebo (P , 0.0001; Table 3).
Plasma glucagon concentrations were no different (P =
0.7482). Again, plasma epinephrine concentrations were un-
altered, but plasma norepinephrine concentrations increased
(P , 0.0001) after diazoxide administration (Table 1). Heart
rates were slightly higher (P , 0.0001), and systolic and di-
astolic blood pressures were slightly lower (both P , 0.0001)
after diazoxide administration (Table 2).
DISCUSSION
Reduced pancreatic b-cell insulin secretion causes hyper-
glycemia in diabetes (1,2). Relative hyperglucagonemia is
thought to also be involved in the pathogenesis of hyper-
glycemia (23–26). Here we demonstrate that partial in-
hibition of insulin secretion, with the KATP channel agonist
(opener) diazoxide, results in glucose intolerance after
a mixed meal with no difference in plasma glucagon con-
centrations in nondiabetic individuals. It also results in
higher plasma glucose concentrations, despite lower glu-
cose infusion rates, after ingestion of the sulfonylurea
glimepiride, with no difference in plasma glucagon con-
centrations in such individuals. These data uniquely (1,2)
document that impairment of insulin secretion, in the ab-
sence of a reduction of b-cell mass and of prior elevated
glucose or fatty acid levels (i.e., glucolipotoxicity), results
in glucose intolerance in humans. Our results also un-
derscore the primary glucoregulatory role of insulin.
Oral glucose tolerance tests in individuals with normal
glucose tolerance, impaired glucose tolerance, and type 2
diabetes have demonstrated an inverse relationship be-
tween increasing plasma glucose concentrations and sup-
pression of plasma glucagon concentrations (27). On the
FIG. 1. Mean 6 SE plasma insulin, C-peptide, glucose, and glucagon
concentrations following a mixed meal after oral administration of
placebo (PBO; ○) or 6.0 mg/kg diazoxide (DZ, ●) in healthy humans.
Insulin (P = 0.0016), C-peptide (P = 0.0287), and glucose (P < 0.0001)
levels differed, but glucagon levels did not (P = 0.6602).
TABLE 1
Plasma epinephrine and norepinephrine concentrations*
Time (min)
Mixed meal Glimepiride
Placebo Diazoxide Placebo Diazoxide
Epinephrine (pg/mL)†
260 29 6 63 0 6 83 6 6 83 0 6 5
230 29 6 52 7 6 83 5 6 82 4 6 6
02 5 6 42 3 6 73 1 6 72 9 6 6
30 18 6 22 0 6 52 9 6 72 3 6 5
60 25 6 82 3 6 53 6 6 82 4 6 6
90 26 6 42 7 6 73 6 6 82 4 6 7
120 22 6 43 0 6 83 4 6 82 9 6 7
150 26 6 53 1 6 73 6 6 83 2 6 8
180 29 6 53 4 6 63 7 6 83 7 6 8
(P = 0.1392) (P = 0.0733)
Norepinephrine (pg/mL)‡
260 175 6 12 184 6 13 188 6 13 174 6 9
230 167 6 10 179 6 15 191 6 12 173 6 8
0 176 6 13 162 6 15 185 6 16 188 6 12
30 189 6 13 220 6 21 188 6 8 199 6 14
60 189 6 13 233 6 23 186 6 10 224 6 11
90 180 6 12 247 6 28 189 6 14 238 6 19
120 163 6 14 223 6 21 187 6 12 236 6 18
150 162 6 10 223 6 21 187 6 12 237 6 14
180 168 6 11 225 6 16 183 6 12 265 6 22
(P , 0.0001) (P , 0.0001)
*Mean 6 SE data are shown with oral administration of placebo or
diazoxide (6.0 mg/kg) at 230 min and a mixed meal (Ensure Plus) at
0 min on two occasions (left) or oral glimepiride (4.0 mg) at 0 min on
another two occasions (right) in healthy humans. †To convert epi-
nephrine to pmol/L, multiply pg/mL by 5.458. ‡To convert norepi-
nephrine to nmol/L, multiply pg/mL by 0.005911.
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in nondiabetic and type 1 diabetic individuals, we sug-
gested that progressively diminishing early b-cell insulin
secretion might account not only for progressively in-
creasing plasma glucose concentrations but also for pro-
gressively decreasing suppression of plasma glucagon
concentrations across this spectrum from normal glucose
tolerance to type 2 diabetes (21). Thus, given evidence that
b-cell secretory products, including insulin, normally re-
strain a-cell glucagon secretion (5–9,14–21), we antici-
pated that partial inhibition of insulin secretion would also
result in higher plasma glucagon, as well as glucose, con-
centrations after the mixed meal and after glimepiride.
That hypothesis was not conﬁrmed.
Despite partially inhibited insulin secretion and higher
plasma glucose levels following the mixed meal after
diazoxide, compared with after placebo, plasma gluca-
gon concentrations were the same. Similarly, despite de-
creased insulin secretion and higher plasma glucose levels
following the sulfonylurea glimepiride after diazoxide,
compared with placebo, plasma glucagon concentrations
declined similarly. (Glucose was infused intravenously to
prevent hypoglycemia after glimepiride ingestion, but the
glucose infusion rates with diazoxide were ;50% of those
with placebo.) In an earlier study (3), partial inhibition of
insulin secretion with diazoxide also raised postabsorptive
plasma glucose concentrations but not postabsorptive
plasma glucagon concentrations.
These ﬁndings do not exclude an inhibitory effect of
b-cell secretion on a-cell glucagon secretion, but suggest
that that the effect is not as potent as other factors. A
greater degree of inhibition of insulin secretion might have
resulted in both hyperglycemia and hyperglucagonemia
after the meal and after glimepiride (as observed in indi-
viduals with absolute endogenous insulin deﬁciency [21]),
but that was not demonstrated in this study of mild insulin
deﬁciency.
Among the weaknesses of this study is that only partial
inhibition of insulin secretion was accomplished with the
dose of diazoxide that was used. However, diazoxide is
a nonselective KATP channel agonist (3), and its dosing is
therefore limited by hypotension. The dose of 6.0 mg/kg
used in this study approximates the maximum tolerable
single dose (3); indeed, heart rates were slightly higher and
blood pressures were slightly lower after diazoxide ad-
ministration. The latter undoubtedly resulted in sym-
pathetic neural activation, as evidenced by a small but
statistically signiﬁcant increase in the plasma norepi-
nephrine concentration. That did not alter basal insulin or
C-peptide levels but may have contributed to the partial
suppression of insulin secretion after the meal and after
glimepiride. Notably, however, there was no increase in
the plasma concentration of the adrenomedullary hor-
mone epinephrine.
In addition, the glucagon radioimmunoassay used re-
acts with species in addition to biologically active 3500-d
glucagon, although increments in measured values are
thought to represent biologically active glucagon (26).
Therefore, it is conceivable that small differences in he-
patic portal venous glucagon concentrations were missed
in our peripheral arterialized venous measurements. How-
ever, our data showed no trends toward higher glucagon
levels. Furthermore, it is conceivable that higher plasma
glucose concentrations might have masked the effects of
lower insulin levels to increase glucagon secretion, but
TABLE 2
Heart rates and systolic and diastolic blood pressures*
Time (min)
Mixed meal Glimepiride
Placebo Diazoxide Placebo Diazoxide
Heart rate (bpm)
260 69 6 47 1 6 27 0 6 47 1 6 3
230 70 6 37 0 6 37 2 6 47 0 6 3
07 3 6 47 7 6 36 9 6 47 0 6 4
30 79 6 58 6 6 46 8 6 47 3 6 4
60 78 6 58 1 6 46 7 6 57 8 6 4
90 77 6 48 4 6 46 8 6 47 4 6 3
120 77 6 68 5 6 46 9 6 57 7 6 4
150 76 6 58 0 6 47 0 6 47 7 6 4
180 74 6 58 1 6 47 5 6 48 4 6 4
(P , 0.0001) (P , 0.0001)
Systolic blood pressure (mmHg)
260 118 6 2 121 6 3 118 6 2 118 6 3
230 116 6 3 121 6 3 122 6 2 126 6 3
0 120 6 3 121 6 3 122 6 2 118 6 2
30 118 6 3 118 6 3 119 6 2 118 6 2
60 119 6 3 117 6 3 120 6 2 118 6 2
90 116 6 3 117 6 3 119 6 2 115 6 3
120 116 6 3 114 6 2 122 6 3 114 6 2
150 115 6 3 112 6 3 119 6 3 115 6 3
180 118 6 3 113 6 3 122 6 3 114 6 3
(P = 0.2173) (P , 0.0001)
Diastolic blood pressure (mmHg)
260 65 6 26 8 6 26 9 6 26 8 6 2
230 66 6 26 9 6 26 8 6 17 3 6 3
06 5 6 36 7 6 26 6 6 26 8 6 2
30 61 6 35 8 6 26 5 6 26 6 6 2
60 60 6 25 9 6 36 8 6 26 1 6 3
90 58 6 26 0 6 26 5 6 26 0 6 3
120 62 6 25 7 6 26 6 6 26 0 6 2
150 63 6 25 8 6 36 8 6 25 9 6 3
180 62 6 25 7 6 26 6 6 26 0 6 3
(P = 0.0339) (P , 0.0001)
*Mean 6 SE data are shown after oral administration of placebo or
diazoxide (6.0 mg/kg) at 230 min and a mixed meal (Ensure Plus) at
0 min on two occasions (left) or oral glimepiride (4.0 mg) on another
two occasions (right) in healthy humans.
FIG. 2. Mean 6 SE plasma insulin, C-peptide, glucose, and glucagon
concentrations after glimepiride (4.0 ng) ingestion after oral adminis-
tration of placebo (PBO; ○) or 6.0 mg/kg diazoxide (DZ, ●) in healthy
humans. Glucose was infused intravenously to prevent hypoglycemia
after glimepiride. Insulin levels tended to differ (P = 0.0649), and
C-peptide (P = 0.0015) and glucose (P < 0.0001) differed, but glucagon
levels did not (P = 0.7482).
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cretion in the pathogenesis of hyperglycemia.
A direct effect, if any, of diazoxide on glucagon secre-
tion in vivo in humans is not known. It is difﬁcult to predict
because diazoxide, a KATP channel opener, and the sulfo-
nylurea tolbutamide, a KATP channel closer, have both
been reported to stimulate glucagon release from isolated
islets at low concentrations and to inhibit glucagon release
from isolated islets at higher concentrations (4). Diazoxide
administration did not alter plasma glucagon concen-
trations before ingestion of a mixed meal or of glimepiride
in the current study, or during a more prolonged post-
absorptive period in our earlier study (3).
Glimepiride raised plasma glucagon concentrations in
the virtual absence of insulin secretion in patients with
type 1 diabetes (21), which implies that KATP channel
closure stimulates a-cell glucagon secretion in humans. If
so, KATP channel opening, with diazoxide, might inhibit
a-cell glucagon secretion in vivo. Diazoxide has been
reported to decrease glucagon release from isolated rat
a-cells (5). Thus, it is theoretically conceivable that an
inhibitory effect of diazoxide precluded increased gluca-
gon secretion triggered by partial inhibition of insulin se-
cretion after a mixed meal and after glimepiride.
In conclusion, these data indicate that partial inhibition
of insulin secretion results in impairment of glucose tol-
erance after a mixed meal and in higher glucose levels
after glimepiride in the absence of a difference in mea-
sured glucagon secretion in humans. They underscore the
primary glucoregulatory role of insulin. For the various
reasons discussed, this is not a deﬁnitive negative study of
the effect of reduced insulin secretion to increase gluca-
gon secretion. Nonetheless, the data support the evidence
that b-cell secretion is not the only regulator of a-cell
glucagon secretion.
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